SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) announced the successful completion of Phase I clinical trial of MRX-5 in Australia, a self-developed oral antibacterial agent in development for the treatment of...
MicuRx Announces the Successful Completion of Phase 1 Clinical Trial of MRX-5 in Australia
Seaking AlphaSeeking Alpha / Seaking Alpha 3 hours ago 1 Views
Comments